Compare Abeona Therapeutics Inc (ABEO) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs MasTec Inc — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $424.33M), while MasTec Inc trades at $273.94 (market cap $21.54B). The key difference: MasTec Inc is far larger — about 50.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | MTZ | |
|---|---|---|
Market Cap | $424.33M | $21.54B |
Sector | Health | Technology |
52-Week High | $7.45 | $437.51 |
52-Week Low | $4.17 | $172.51 |
Enterprise Value | $279.23M | $24.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
MasTec (MTZ) trades at $272.46, up 5.35% with strong YTD performance of 25.9%, outperforming the S&P 500. The stock shows bearish technical signals but maintains robust fundamentals with record Q2 2026 revenue of $4.37B and 40% EBITDA growth. Recent acquisition of The Superior Group for $1.65B expands critical infrastructure capabilities. The company raised 2026 guidance citing strong infrastructure demand and a record $21.4B backlog.
Despite technical weakness, MasTec's strong earnings momentum and 88.9% analyst buy rating with $447.91 price target suggest significant upside. Key risks include execution of large acquisitions and communications segment delays. The stock offers exposure to infrastructure growth trends but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
